Loading...
XSHE300109
Market cap895mUSD
Jan 13, Last price  
13.55CNY
1D
0.74%
1Q
13.01%
Jan 2017
-63.86%
IPO
-10.72%
Name

Boai NKY Medical Holdings Ltd

Chart & Performance

D1W1MN
XSHE:300109 chart
P/E
13.32
P/S
4.15
EPS
1.02
Div Yield, %
2.47%
Shrs. gr., 5y
18.30%
Rev. gr., 5y
17.79%
Revenues
1.58b
+6.58%
83,436,362108,683,239130,085,199163,311,320190,734,549212,847,087209,389,954253,343,476290,639,760400,618,888488,581,464698,283,178924,426,291978,529,1091,220,275,2461,485,693,9051,583,417,842
Net income
493m
+69.16%
6,261,65310,348,85318,208,38023,026,68024,921,07520,073,29820,165,06630,117,86256,985,65980,039,82992,823,18989,546,168122,796,22632,643,386293,119,661291,463,635493,027,339
CFO
488m
+93.93%
9,560,192028,571,73310,052,6243,941,49820,648,17623,172,95546,599,08264,116,278114,144,48847,279,35948,810,50979,638,058266,871,09043,440,305251,768,613488,252,026
Dividend
Jun 07, 20241.04 CNY/sh
Earnings
May 23, 2025

Profile

Boai NKY Medical Holdings Ltd. develops, manufactures, and sells polyvinylpyrrolidone (PVP) series products worldwide. The company offers KoVidone and PolyKoVidone line of products representing Povidone, Crospovidone, and Copovidone pharmaceutical excipients; OraRez line of PVM/MA copolymer and derivatives representing functional polymers for bioadhesive/mucoadhesive applications; KoVidone-1 broad spectrum biocidal, antifungal, and antiviral agents; and pharmaceutical solvents and intermediates. It also offers polymers, vinyl and vinyl ether compounds, PolyViscol, KoVidone I, WhiVidone, and PVPP. Its products are used in pharma, industrial, oral care, cosmetics, food and beverage, and other sectors. The company was formerly known as Boai NKY Pharmaceuticals Ltd. and changed its name to NKY medical holding Ltd. in March 2016. Boai NKY Medical Holdings Ltd. was founded in 1987 and is based in Heping, China.
URL
http://www.nkygroup.cn/
IPO date
Aug 25, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,583,418
6.58%
1,485,694
21.75%
Cost of revenue
853,823
956,944
Unusual Expense (Income)
NOPBT
729,595
528,750
NOPBT Margin
46.08%
35.59%
Operating Taxes
99,575
107,036
Tax Rate
13.65%
20.24%
NOPAT
630,020
421,714
Net income
493,027
69.16%
291,464
-0.56%
Dividends
(161,953)
(167,836)
Dividend yield
1.77%
2.02%
Proceeds from repurchase of equity
(7,080)
BB yield
0.08%
Debt
Debt current
15,794
22,925
Long-term debt
33,432
50,523
Deferred revenue
39,951
Other long-term liabilities
35,947
223
Net debt
(525,935)
(565,815)
Cash flow
Cash from operating activities
488,252
251,769
CAPEX
Cash from investing activities
(544,640)
Cash from financing activities
(183,711)
FCF
75,369
300,243
Balance
Cash
324,972
576,923
Long term investments
250,189
62,341
Excess cash
495,990
564,979
Stockholders' equity
1,304,850
1,104,094
Invested Capital
3,108,396
2,556,864
ROIC
22.24%
17.18%
ROCE
20.22%
16.91%
EV
Common stock shares outstanding
506,002
342,898
Price
18.04
-25.45%
24.20
11.01%
Market cap
9,128,271
10.00%
8,298,141
13.98%
EV
8,576,375
7,732,326
EBITDA
803,813
590,693
EV/EBITDA
10.67
13.09
Interest
2,990
2,618
Interest/NOPBT
0.41%
0.50%